We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Antihypertensive treatment, high triglycerides, and low high-density lipoprotein cholesterol and risk of ischemic heart disease mortality: a 16-year follow-up in the Copenhagen male study.
Metabolic Syndrome and related Disorders 2010 June
OBJECTIVE: The aim of this study was to test the hypothesis that metabolic syndrome dyslipidemia is a major risk factor for ischemic heart disease (IHD) mortality among men taking antihypertensive medication.
METHODS: This was a 16-year follow up of 2,986 men 53-75 years old without overt cardiovascular disease; 357 men used antihypertensive medicine. Potential risk factors were type of baseline medication, blood pressure, diabetes, fasting serum triglycerides (TG), high-density lipoprotein (HDL-C) and total cholesterol, glucosuria, electrocardiogram (ECG) changes, cancer history, body mass index, alcohol and tobacco use, leisure time physical activity, social class, and age. The main outcome was IHD mortality.
RESULTS: Men treated for hypertension had a two-fold higher cumulative incidence of IHD mortality during the follow up compared to other men (12.0% vs, 5.8%). Dyslipidemia was defined as TG >or=1.70 mmol/L or HDL-C
CONCLUSIONS: TG and HDL-C dyslipidemia were strong effect modifiers. Men on antihypertensive medication had no increased risk of IHD mortality compared to untreated normotensive men, provided they were free from high TG and low HDL-C dyslipidemia.
METHODS: This was a 16-year follow up of 2,986 men 53-75 years old without overt cardiovascular disease; 357 men used antihypertensive medicine. Potential risk factors were type of baseline medication, blood pressure, diabetes, fasting serum triglycerides (TG), high-density lipoprotein (HDL-C) and total cholesterol, glucosuria, electrocardiogram (ECG) changes, cancer history, body mass index, alcohol and tobacco use, leisure time physical activity, social class, and age. The main outcome was IHD mortality.
RESULTS: Men treated for hypertension had a two-fold higher cumulative incidence of IHD mortality during the follow up compared to other men (12.0% vs, 5.8%). Dyslipidemia was defined as TG >or=1.70 mmol/L or HDL-C
CONCLUSIONS: TG and HDL-C dyslipidemia were strong effect modifiers. Men on antihypertensive medication had no increased risk of IHD mortality compared to untreated normotensive men, provided they were free from high TG and low HDL-C dyslipidemia.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app